Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne

• Status: Completed
• Trial end date: 2003-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with facial acne vulgaris.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BioWest Therapeutics Inc
• Treatments: Omiganan pentahydrochloride; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Males and females 12 years and older

• Presence of inflammatory and non-inflammatory lesions

Exclusion Criteria:

• Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.)

• Active facial cysts or any nodulocystic lesions